1. High-Dose Oral Medroxyprogesterone Acetate or Tamoxifen as Adjuvant Hormone Therapy for Node-Negative Early-Stage Breast Cancer: Randomized Trial with 7-Year Update
- Author
-
Jean-Luc Canon, D. Focan-Henrard, Christian Focan, Françoise Majois, Jean-Pierre Lobelle, Giuseppe Cusumano, and Marc Beauduin
- Subjects
Cancer Research ,medicine.medical_specialty ,Time Factors ,Antineoplastic Agents, Hormonal ,medicine.medical_treatment ,Urology ,Breast Neoplasms ,Medroxyprogesterone Acetate ,Risk Assessment ,Drug Administration Schedule ,law.invention ,Breast cancer ,Belgium ,Randomized controlled trial ,Reference Values ,law ,medicine ,Humans ,Medroxyprogesterone acetate ,Survival rate ,Mastectomy ,Survival analysis ,Aged ,Neoplasm Staging ,Probability ,Analysis of Variance ,Chemotherapy ,Dose-Response Relationship, Drug ,business.industry ,Biopsy, Needle ,Age Factors ,Middle Aged ,medicine.disease ,Immunohistochemistry ,Survival Analysis ,Surgery ,Tamoxifen ,Treatment Outcome ,Oncology ,Chemotherapy, Adjuvant ,Multivariate Analysis ,Female ,Lymph Nodes ,Hormone therapy ,business ,Follow-Up Studies ,medicine.drug - Abstract
A randomized adjuvant trial compared tamoxifen 20 mg daily for 5 years with high-dose oral medroxyprogesterone acetate (MPA) 1 g orally for 9 months. One hundred ninety-four patients with histologically proven primary node-negative breast carcinoma were enrolled between December 1990 and October 1996, with 98 patients randomized into the tamoxifen arm and 96 into the MPA arm. At a median follow-up of 86 months, 25 relapses and 13 deaths were recorded. The relapse-free survival rate at 7 years in the tamoxifen arm was 93%, versus 81% in the MPA arm (P = 0.02). The difference was observed in patients with stage T2 disease (100% in the tamoxifen group vs. 64% in the MPA group; P = 0.01), in younger and/or premenopausal patients (in patients50 years of age, 100% in the tamoxifen arm vs. 81% in the MPA arm [P = 0.02], and in patientsor = 50 years of age, 90% in the tamoxifen arm vs. 82% in the MPA arm [P = 0.16]). Also, the overall survival rate at 7 years was lower in women50 years of age (P = 0.04).
- Published
- 2004
- Full Text
- View/download PDF